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Abstract
Sweet's syndrome (the eponym for acute febrile neutrophilic dermatosis) is characterized by a
constellation of clinical symptoms, physical features, and pathologic findings which include fever,
neutrophilia, tender erythematous skin lesions (papules, nodules, and plaques), and a diffuse
infiltrate consisting predominantly of mature neutrophils that are typically located in the upper
dermis. Several hundreds cases of Sweet's syndrome have been published. Sweet's syndrome
presents in three clinical settings: classical (or idiopathic), malignancy-associated, and drug-induced.
Classical Sweet's syndrome (CSS) usually presents in women between the age of 30 to 50 years, it
is often preceded by an upper respiratory tract infection and may be associated with inflammatory
bowel disease and pregnancy. Approximately one-third of patients with CSS experience recurrence
of the dermatosis. The malignancy-associated Sweet's syndrome (MASS) can occur as a
paraneoplastic syndrome in patients with an established cancer or individuals whose Sweet's
syndrome-related hematologic dyscrasia or solid tumor was previously undiscovered; MASS is
most commonly related to acute myelogenous leukemia. The dermatosis can precede, follow, or
appear concurrent with the diagnosis of the patient's cancer. Hence, MASS can be the cutaneous
harbinger of either an undiagnosed visceral malignancy in a previously cancer-free individual or an
unsuspected cancer recurrence in an oncology patient. Drug-induced Sweet's syndrome (DISS)
most commonly occurs in patients who have been treated with granulocyte-colony stimulating
factor, however, other medications may also be associated with DISS. The pathogenesis of Sweet's
syndrome may be multifactorial and still remains to be definitively established. Clinical and
laboratory evidence suggests that cytokines have an etiologic role. Systemic corticosteroids are the
therapeutic gold standard for Sweet's syndrome. After initiation of treatment with systemic
corticosteroids, there is a prompt response consisting of dramatic improvement of both the
dermatosis-related symptoms and skin lesions. Topical application of high potency corticosteroids
or intralesional corticosteroids may be efficacious for treating localized lesions. Other first-line oral
systemic agents are potassium iodide and colchicine. Second-line oral systemic agents include
indomethacin, clofazimine, cyclosporine, and dapsone. The symptoms and lesions of Sweet's
syndrome may resolved spontaneously, without any therapeutic intervention; however, recurrence
may follow either spontaneous remission or therapy-induced clinical resolution.
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Disease name and synonyms
Sweet's syndrome
Acute febrile neutrophilic dermatosis
Gomm-Button disease
Introduction
The syndrome was originally described by Dr. Robert
Douglas Sweet in the August-September 1964 issue of the
British Journal of Dermatology as an "acute febrile neu-
trophilic dermatosis" [1-10]. This seminal paper summa-
rizes the cardinal features of "a distinctive and fairly severe
illness" that he had encountered in eight women during
the 15-year period from 1949 to 1964. In his disease
defining report, Dr. Sweet commented that "the condition
was known in my department as the Gomm-Button dis-
ease, a title some may still prefer to that which heads this
paper;" this nomenclature was "in eponymous honor of
the first two patients" with the disease in Dr. Sweet's
department [8]. Subsequently, Dr. Sweet recommended
that the name of the condition remain descriptive; how-
ever, in spite of his suggestion, 'Sweet's syndrome' has
become the established eponym for this acute febrile neu-
trophilic dermatosis [1-10]. Several hundreds of reports of
Sweet's syndrome patients have since been published [11-
435].
Definition and diagnostic criteria
Sweet's syndrome can present in several clinical settings:
classical (or idiopathic) Sweet's syndrome, malignancy-
associated Sweet's syndrome, and drug-induced Sweet's
syndrome.
Classical Sweet's syndrome
Classical Sweet's syndrome is characterized by a constella-
tion of clinical symptoms, physical features, and patho-
logic findings which include pyrexia, elevated neutrophil
count, tender erythematous skin lesions (papules, nod-
ules, and plaques), and a diffuse infiltrate consisting pre-
dominantly of mature neutrophils typically located in the
upper dermis. The symptoms and clinical manifestations
typically respond promptly after initiation of systemic
corticosteroid therapy (Figures 1 and 2).
The diagnostic criteria for classical Sweet's syndrome were
originally proposed by Su and Liu [11] in 1986. They were
modified by von den Driesch [12] in 1994 (Table 1)
[13,14]. Additional cases of Sweet's syndrome continue to
appear in the medical literature since Sweet's original
paper [1-435].
Malignancy-associated Sweet's syndrome
Shapiro  et al [24] reported the first patient with solid
tumor-associated Sweet's syndrome, a 58-year-old man
(a, b, and c). Tender, red Sweet's syndrome lesions in a  woman with the classical form of the dermatosis Figure 2
(a, b, and c). Tender, red Sweet's syndrome lesions in a 
woman with the classical form of the dermatosis. A closer 
view of the Sweet's syndrome lesions from the woman in Fig-
ure 1. The skin lesions improved rapidly after corticosteroid 
therapy was initiated. There is an erythematous plaque, 5 cm 
in diameter, with a pseudovesicular appearance on the left 
shoulder of the patient (a). A nodular lesion, 1 cm in diame-
ter, is present on the lateral left arm (b). Painful, erythema-
tous, pseudovesicular plaques of acute febrile neutrophilic 
dermatosis are present on the left hand (c). (From [10] 
Cohen PR, Almeida L, Kurzrock R: Acute febrile neutrophilic 
dermatosis. Am Fam Physician 1989;39(3):199–204. Copyright 
1989, Reprinted with permission from Academy of American Fam-
ily Physicians, Leewood, Kansas.)
Sweet's syndrome skin lesions in a woman with classical  Sweet's syndrome Figure 1
Sweet's syndrome skin lesions in a woman with classical 
Sweet's syndrome. Cutaneous lesions of classical Sweet's 
syndrome on the left hand, left proximal arm and left shoul-
der in a 48-year-old woman with pyrexia, neutropenia, and a 
recent respiratory tract infection. (From [10] Cohen PR, 
Almeida L, Kurzrock R: Acute febrile neutrophilic dermato-
sis. Am Fam Physician 1989;39(3):199–204. Copyright 1989, 
Reprinted with permission from Academy of American Family Phy-
sicians, Leewood, Kansas.)Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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with testicular carcinoma, in 1971. However, prior to Dr.
Sweet's 1964 publication, Costello et al [29] described a
16-year-old girl with acute myelogenous leukemia and
recurrent cutaneous lesions of variable morphologies in
1955. Retrospectively, several authors have acknowledged
that Costello et al's patient represents the first report of
malignancy-associated Sweet's syndrome. It was not until
18 years later, in 1973, that Matta and Kurban [25]
reported two women whose biopsy-confirmed Sweet's
syndrome lesions were the presenting manifestation of
their previously unsuspected acute leukemia.
Malignancy-associated Sweet's syndrome was initially
included as a subset of classical Sweet's syndrome. How-
ever, since many of the cases of Sweet's syndrome are can-
cer-related, several authors have chosen to distinguish
between the classical form and the malignancy-associated
form of this condition. The onset of Sweet's syndrome can
precede, follow, or appear concurrent with the diagnosis
of the patient's neoplasm. Indeed, the dermatosis can be
the cutaneous harbinger of either an undiagnosed visceral
malignancy in a previously cancer-free individual or an
unsuspected cancer recurrence in an oncology patient.
Drug-induced Sweet's syndrome
Su and Liu [11] reported the first patient with drug-
induced Sweet's syndrome in 1986; the associated medi-
cation was trimethoprim-sulfamethoxazole. A decade
later, criteria for drug-induced Sweet's syndrome were
established by Walker and Cohen [13]. The most fre-
quently implicated drug is granulocyte-colony stimulat-
ing factor. However, several other medications – albiet
less often – have been observed to promote the develop-
ment of Sweet's syndrome.
Diagnostic criteria for drug-induced Sweet's syndrome
were presented by Walker and Cohen [13] in 1996 (Table
1).
Epidemiology
The distribution of Sweet's syndrome cases is worldwide
and there is no racial predilection (Table 2) [1,2,12,13,15-
20,30,31].
Classical or idiopathic Sweet's syndrome predominantly
affects in women. It may be associated with infection
(upper respiratory tract or gastrointestinal tract), inflam-
matory bowel disease, or pregnancy [13,15]. Recurrence
of the dermatosis is noted in approximately one-third of
individuals.
The initial episode of classical Sweet's syndrome most fre-
quently occurs between the ages of 30 to 60 years. How-
ever, classical Sweet's syndrome has been reported in
children (as young as 7 weeks of age) and younger adults
[32-48]. Brothers who developed the dermatosis at 10 and
15 days of age are the youngest Sweet's syndrome patients
reported [46].
Malignancy-associated Sweet's syndrome has been pub-
lished as descriptions of individual oncology patients
with Sweet's syndrome, observations from small series of
Sweet's syndrome patients with cancer, and retrospective
reviews in which the features from multiple Sweet's syn-
drome patients (some with malignancy) are summarized.
In 1993, Cohen and Kurzrock [15] reviewed and com-
bined the data from 15 studies of patients with Sweet's
syndrome studies (each containing between ten to 48
individuals) in order to more accurately define the inci-
Table 1: Diagnostic criteria for classical Sweet's syndrome versus drug-induced Sweet's syndrome
Classicala Drug-inducedb
(1) Abrupt onset of painful erythematous plaques or nodules (A) Abrupt onset of painful erythematous plaques or nodules
(2) Histopathologic evidence of a dense neutrophilic infiltrate without 
evidence of leukocytoclastic vasculitis
(B) Histopathologic evidence of a dense neutrophilic infiltrate without 
evidence of leukocytoclastic vasculitis
(3) Pyrexia >38°C (C) Pyrexia >38°C
(4) Association with an underlying hematologic or visceral malignancy, 
inflammatory disease, or pregnancy, OR preceded by an upper 
respiratory or gastrointestinal infection or vaccination
(D) Temporal relationship between drug ingestion and clinical 
presentation, OR temporally-related recurrence after oral challenge
(5) Excellent response to treatment with systemic corticosteroids or 
potassium iodide
(E) Temporally-related resolution of lesions after drug withdrawal or 
treatment with systemic corticosteroids
(6) Abnormal laboratory values at presentation (three of four): 
erythrocyte sedimentation rate >20 mm/hr; positive C-reactive protein; 
>8,000 leukocytes; >70% neutrophils
aThe presence of both major criteria (1 and 2), and two of the four minor criteria (3, 4, 5, and 6) is required in order to establish the diagnosis of 
classical Sweet's syndrome; the patients with malignancy-associated Sweet's syndrome are included with the patients with classical Sweet's 
syndrome in this list of diagnostic criteria.
bAll five criteria (A, B, C, D, and E) are required for the diagnosis of drug-induced Sweet's syndrome.
Source [13]: Adapted with permission from Walker DC, Cohen PR: Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic 
dermatosis: case report and review of drug induced Sweet's syndrome. J Am Acad Dermatol 1996;34:918–923. Copyright 1996, Reprinted with 
permission from the American Academy of Dermatology, Inc., Elsevier Ltd, Oxford, United Kingdom.Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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dence of malignancy-associated Sweet's syndrome. They
found that 21 percent of the patients with Sweet's syn-
drome (96 of 448 individuals) had either a hematologic
malignancy or a solid tumor.
Several investigators consider it appropriate to distinguish
malignancy-associated Sweet's syndrome from the classi-
cal form of this disease. Malignancy-associated Sweet's
syndrome occurs as frequently in men as in women. Also,
it is less often preceded by an upper respiratory tract infec-
tion. In addition, the onset or recurrence of many of the
cases of malignancy-associated Sweet's syndrome is tem-
porally associated with the discovery or relapse of cancer.
Specifically, in these individuals, either the new discovery
of an unsuspected neoplasm in a patient in whom cancer
has not previously been diagnosed or the recurrence of
malignancy in a patient with a previously established can-
cer is temporally associated with the appearance of the
dermatosis [15,49-60].
Malignancy-associated Sweet's syndrome is most often
associated with acute myelogenous leukemia [61,62].
However, in patients with hematologic disorders, Sweet's
syndrome can occur in one or more of the following
forms: a paraneoplastic syndrome, a drug-induced derma-
tosis, or a condition whose skin lesions concurrently dem-
onstrate leukemia cutis. Carcinomas of the genitourinary
organs, breast, and gastrointestinal tract are the most fre-
quently occurring cancers in Sweet's syndrome patients
with dermatosis-related solid tumors [1,2,63-66].
Drug-induced Sweet's syndrome
Several medications have been associated with the subse-
quent development of drug-induced Sweet's syndrome
(Table 3) [1,2,11,13,17,39,41,67-
124,398,401,404,417,426,435] (Figure 3). However, the
drug-induced variant of the dermatosis has most fre-
quently been observed in patients following the adminis-
tration of granulocyte-colony stimulating factor.
Table 2: Clinical features in patients with Sweet's syndrome
Clinical Form
Characteristic Classicala Hematologic malignancya Solid tumora Drug-inducedb
Epidemiology
Women 80 50 59 71
Prior upper respiratory tract infection 75–90 16 20 21
Recurrencec 30 69 41 67
Clinical symptoms
Feverd 80–90 88 79 100
Musculoskeletal involvement 12–56 26 34 21
Ocular involvement 17–72 7 15 21
Lesion location
Upper extremities 80 89 97 71
Head and neck 50 63 52 43
Trunk and back 30 42 33 50
Lower extremities Infrequent 49 48 36
Oral mucous membranes 2 12 3 7
Laboratory findings
Neutrophiliae 80 47 60 38
Elevated erythrocyte sedimentation ratef 90 100 95 100
Anemiag Infrequent 82 83 100
Abnormal platelet counth Infrequent 68 50 50
Abnormal renal functioni 11–50 15 7 0
aPercentages for classical, hematologic malignancy, and solid tumor associated Sweet's syndrome adapted with permission from Cohen PR, 
Kurzrock R: Sweet's syndrome and cancer. Clin Dermatol 1993;11:149–157 [15]. Copyright 1993, Reprinted with permission from Elsevier Ltd, Oxford, 
United Kingdom.
bPercentages for drug-induced Sweet's syndrome adapted with permission from Walker DC, Cohen PR: Trimethoprim-sulfamethoxazole-associated 
acute febrile neutrophilic dermatosis: case report and review of drug induced Sweet's syndrome. J Am Acad Dermatol 1996;34:918–923 [13]. 
Copyright 1996, Reprinted with permission from the American Academy of Dermatology, Inc., Elsevier Ltd, Oxford, United Kingdom.
cRecurrence following oral rechallenge testing in the patients with drug-induced Sweet's syndrome.
dTemperature greater than 38°C.
eNeutrophil count greater than 6,000 cells/ul.
fErythrocyte sedimentation rate greater than 20 mm/hr.
gHemoglobin less than 13 g/dl in men and less than 12 g/dl in women.
hPlatelet count less than 150,000/ul or greater than 500,000/ul.
iThis includes hematuria, proteinuria, and renal insufficiency.Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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Recurrence of the dermatosis is often noted when the
patient is rechallenged with the associated drug. However,
once the causative agent has been discontinued, the dis-
ease manifestations frequently improve.
Clinical description
Symptoms
Sweet's syndrome patients may appear dramatically ill.
Fever is the most frequent symptom. Indeed, the skin
eruption of Sweet's syndrome is usually accompanied by
fever and leukocytosis. However, the cutaneous manifes-
tations of the disease may be preceded by several days to
weeks of fever. Alternatively, pyrexia can be concurrently
present throughout the entire episode of the dermatosis.
Also, in some patients with biopsy-confirmed malig-
nancy-associated Sweet's syndrome, fever may be absent.
Other Sweet's syndrome-associated symptoms, such as
arthralgia, general malaise, headache, and myalgia may
also be present [1,2,23].
Skin lesions
Skin lesions of Sweet's syndrome are typically tender.
They appear as painful, red or purple-red, papules or nod-
ules. Larger lesions may develop into plaques (Figures 1
and 2). The eruption is often distributed asymetrically. It
presents as either a single lesion or multiple lesions. The
most frequent lesion locations are the upper extremities,
face, and neck (Figure 4) [1,10].
The Sweet's syndrome lesions have a transparent, vesicle-
like appearance because of the pronounced edema in the
upper dermis; some lesions are morphologically similar
to bullae [401,419]. Central clearing may lead to annular
or arcuate patterns in latter stages. In patients with malig-
Table 3: Medications associated with drug-induced Sweet's syndrome [a-c]
Antibiotics Minocycline [110-112]
Nitrofurantoin [113]
Norfloxacin [114]
Ofloxacin [115]
Quinupristin/dalfopristin [118]
Trimethoprim-sulfamethoxazole [11,13]
Antiepileptics Carbemazepine [17]
Diazepam [86]
Antihuman immunodeficiency virus drugs Abacavir (synthetic carbocyclic nucleoside analogue) [69]
Antihypertensives Hydralazine [107]
Antineoplastics Bortezomib [d] [78-79]
Imatinib mesylate [e] [108,109,401]
Lenalidomide [f] [426]
Antipsychotics Clozapine [82]
Antithyroid hormone synthesis drugs Propylthiouracil [117]
Colony stimulating factors Granulocyte-colony stimulating factor [39,41,89-105,398]
Granulocyte-macrophage-colony stimulating factor [105,106]
Pegfilgrastim [g] [116]
Contraceptives [83] Levonorgestrel/ethinyl estradiol (Triphasil) [84]
Levonorgestrel-releasing intrauterine system (Mirena) [85]
Diuretics Furosemide [88]
Nonsteroidal anti-inflammatory agents Celecoxib [80]
Diclofenac [87]
Retinoids All-trans retinoic acid [70-77,417]
13-cis-retinoic acid [81,404]
[a] The possibility of acyclovir-induced Sweet's syndrome cannot be completely ruled out in a 13-year-old girl with systemic lupus erythematosus 
(that had been diagnosed 3 months earlier and was being treated with oral prednisolone and azathioprine) whose Sweet's syndrome lesions 
appeared 5 days after beginning intravenous acyclovir treatment for a herpes zoster infection [119].
[b] Photodistributed neutrophilic dermatosis with overlapping features of Sweet's syndrome, acute generalized exanthematous pustulosis and sterile 
neutrophilic folliculitis with perifollicular vasculopathy developed in a patient who had received antidepressant (amoxapine and citalopram) and 
anxiolytic (perphenazine) therapy [120].
[c] Additional reports have attributed Sweet's syndrome to medications (minocycline [121], furosemide [122], and hydralazine [123,124]); however, 
they did not fulfill the criteria proposed by Walker and Cohen [13] for drug-induced Sweet's syndrome.
[d] This drug is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian cells. It is indicated for the treatment of 
multiple myeloma patients.
[e] This drug is a protein-tyrosine kinase inhibitor that inhibits the bcr-abl tyrosine kinase, the constitutive abnormal tyrosine kinase created by the 
Philadelphia chromosome abnormality in chronic myeloid leukemia.
[f] This drug is an amino-substituted analogue of thalidomide. It is an immunomodulatory agent with anti-angiogenic and antineoplastic properties. It 
is indicated for the treatment of: (1) multiple myeloma and (2) transfusion dependent anemia due to low-risk or intermediate-risk myelodysplastic 
syndromes.
[g] This drug is a covalent conjugate of recombinant methionyl human granulocyte-colony stimulating factor (Filgrastim) and 
monomethoxypolyethylene.Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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nancy-associated Sweet's syndrome, the lesions may
appear bullous, become ulcerated, and/or mimic the mor-
phologic features of pyoderma gangrenosum
[133,134,401].
The individual Sweet's syndrome lesions enlarge and may
coalesce to form irregular, sharply border plaques over a
period of days to weeks. Subsequently, either spontane-
ously or after treatment, the lesions usually resolve with-
(a and b). Recurrent Sweet's syndrome in a man with antiphospholipid syndrome Figure 4
(a and b). Recurrent Sweet's syndrome in a man with antiphospholipid syndrome. A 65-year-old white man with a 7-year his-
tory of recurrent Sweet's syndrome and antiphospholipid syndrome (initially manifested by multiple pulmonary emboli and sub-
sequently managed with chronic coumadin therapy). Painful, red, biopsy-confirmed, pseudovesicular nodules and plaques of 
Sweet's syndrome are present on the posterior neck (a), chest, and upper arm (b). Although the Sweet's syndrome skin lesions 
resolved after the initiation of oral prednisone (60 mg/day), they recurred when the dose of the drug was subsequently 
tapered; potassium iodide, colchicine, dapsone, antimalarials, azathioprine, methotrexate, retinoids, and nonsteroidal anti-
inflammatory agents were not effective as corticosteroid-sparing agents. (From [1] Cohen PR, Kurzrock R: Sweet's syndrome 
revisited: a review of disease concepts. Int J Dermatol 2003;42:761–778. Copyright 2003, Reprinted with permission from the Inter-
national Society of Dermatology, Blackwell Publishing, Oxford, United Kingdom.)
(a, b, and c). Drug-induced Sweet's syndrome with photodistributed skin lesions Figure 3
(a, b, and c). Drug-induced Sweet's syndrome with photodistributed skin lesions. Photodistributed drug-induced Sweet's syn-
drome in a 50-year-old woman with trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis. Distant 
(a) and closer (b) views of Sweet's syndrome lesions located on the sun-exposed areas of the arms, hands, and upper chest are 
shown. The biopsy specimen (c) shows a confluent neutrophilic infiltrate in the reticular dermis and edema in the papillary der-
mis (hematoxylin and eosin, × 50). (From [13] Walker DC, Cohen PR: Trimethoprim-sulfamethoxazole-associated acute 
febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol 1996;34:918–
923. Copyright 1996, Reprinted with permission from the American Academy of Dermatology, Inc, Elsevier Ltd, Oxford, United Kingdom.)Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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out scarring. In one-third to two-thirds of patients, lesions
associated with recurrent episodes of Sweet's syndrome
occur [1,2,135,136].
Skin hypersensitivity, also referred to as cutaneous
pathergy, is a Sweet's syndrome-associated feature charac-
terized by dermatosis-associated skin lesions appearing at
sites of cutaneous trauma [1,2,410,432]. These include the
sites where procedures such as biopsies [20], intravenous
catheter placement [20,400], vaccination [419], and veni-
puncture have been performed [12,17,20,37,137,138].
Sweet's syndrome lesions have also been observed at the
locations of cat scratches and insect bites [20], areas that
have received radiation therapy (Figure 5) [23,139-141],
and places that have been contacted by sensitizing antigens
[137,142]. Lesions have also been photodistributed (Fig-
ures 3a and 3b) or localized to the site of a prior photo-
toxic reaction (sunburn) in some Sweet's syndrome
patients [13,20,98,143-145]. Occasionally, Sweet's syn-
drome lesions have appeared on the arm affected by post-
mastectomy lymphedema [100,146,414].
In addition to pseudovesicular papules, plaques, and nod-
ules, Sweet's syndrome can appear as a pustular dermato-
sis [147]. The lesions appear as either erythematous-based
pustules or tiny pustules on the tops of red papules. This
clinical variant of Sweet's syndrome probably also
includes the "pustular eruption of ulcerative colitis" that
has previously been described in some of the patients with
this inflammatory bowel disease [1,148].
When the clinical lesions of the dermatosis are predomi-
nantly restricted to the dorsal hands, this localized, pustu-
lar variant of Sweet's syndrome has been referred to as
(a and b). Radiotherapy-related Sweet's syndrome skin lesions in a woman with malignancy-associated Sweet's syndrome Figure 5
(a and b). Radiotherapy-related Sweet's syndrome skin lesions in a woman with malignancy-associated Sweet's syndrome. Radiotherapy 
associated-exacerbated Sweet's syndrome in a patient with chronic lymphocytic leukemia and cutaneous squamous cell carcinoma. This 
biopsy-confirmed culture-negative, erythematous-based hemorrhagic, and vesicular-appearing Sweet's syndrome lesion extends from the 
dorsal (a) to the palmar (b) surface of the radial side of the right index finger and involves the skin between the metacarpal-phalangeal 
joint and the proximal interphalangeal joint of a 77-year-old woman. She has a prior medical history of hypothyroidism for which she 
receives daily Synthroid. Twenty-four months earlier, she had been diagnosed with chronic lymphocytic leukemia, which is adequately 
being managed with 2 mg of Myleran each day; her current white blood cell count of 51,800 cells/mm3 consists of 79% neutrophils, 15% 
bands, and 2% lymphocytes. More recently (3 months previously), a biopsy confirmed (at both initial microscopic evaluation and subse-
quent consultation pathology review) cutaneous squamous cell carcinoma involving the left index finger. She was started on an oral anti-
biotic (ciprofloxaxin), and radiotherapy (in fractionated doses over a period of 3 weeks) to the left index finger tumor was performed; 
during this treatment, a clinically similar-appearing lesion whose "presentation was suspicious for squamous cell carcinoma" began to 
develop on her right index finger. Based only on the lesion's morphologic characteristics, a single treatment with radiotherapy was also 
given; promptly thereafter, the right index finger lesion rapidly increased in size. Within a week, the lesion on the right index finger (as 
shown in a and b) had grown to a 4- × 4-cm pseudovesicular nodule that nearly involved the entire circumference of the digit and she was 
referred to the dermatology clinic. The lesion was painful and her leukocyte count was markedly elevated; however, she was (and had 
been) afebrile. Lesional biopsies for microscopic and culture evaluation were performed. Because the diagnosis of Sweet's syndrome was 
suspected, daily oral corticosteroid therapy with 60 mg prednisone was started. Oral cephalexin (250 mg 4 times each day for 7 days) and 
topical 2% mupirocin ointment (3 times each day) were also given. After a week of therapy, the lesion was greatly improved: it was no 
longer tender and it had decreased in size. Subsequently, the lesion completely resolved. The dose of prednisone was tapered during the 
next 5 weeks and then discontinued. (From [23] Cohen PR, Kurzrock R: Sweet's syndrome: a neutrophilic dermatosis classically associ-
ated with acute onset and fever. Clin Dermatol 2000;18:265–282. Copyright 2000, Reprinted with permission from Elsevier Ltd, Oxford, United 
Kingdom.)Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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either "neutrophilic dermatosis of the dorsal hands" or
"pustular vasculitis of the dorsal hands" [3,149-
154,401,402,408,420,427]. The morphology and
response to treatment of the dermatosis-associated lesions
reported as neutrophilic dermatosis of the dorsal hands
are similar to those of Sweet's syndrome. The lesions rap-
idly resolve after systemic corticosteroids and/or dapsone
therapy is initiated. Resolution of lesions has also been
observed spontaneously [420] or following therapy with
either topical corticosteroids [401], systemic colchicine
[401], or systemic indomethacin [427]. In addition, con-
current lesions were located on either their oral mucosa,
arm, leg, back, and/or face of several patients with this
form of the disease [3,155-163,401,420].
Subcutaneous Sweet's syndrome is characterized by skin
lesions which usually present as erythematous, tender der-
mal nodules on the extremities [4,8,12,17,99,119,164-
185,397]. The lesions often mimic erythema nodosum
when they are located on the legs [170]. Even in a patient
whose Sweet's syndrome has previously been biopsy-con-
firmed, tissue evaluation of one or more new dermal nod-
ules may be necessary to establish the correct diagnosis
since Sweet's syndrome can present concurrently (Figures
6 and 7) [21,125,187-189] or sequentially [170] with ery-
thema nodosum [1,2,4,17,21,187,190,403].
Extracutaneous manifestations
Bones, central nervous system, ears, eyes, kidneys, intes-
tines, liver, heart, lung, mouth, muscles, and spleen can be
the sites of extracutaneous manifestations of Sweet's syn-
drome (Table 4)
[12,16,17,20,25,26,32,33,44,73,75,88,101,117,138,139,
165,202,203,205,212-257,421,423,434]. In addition,
dermatosis-related sterile osteomyelitis has been reported
in children.
Ocular manifestations may be the presenting feature of
Sweet's syndrome. The incidence of ocular involvement
(such as conjunctivitis) is variable in classical Sweet's syn-
drome. However, ocular lesions of Sweet's syndrome are
uncommon in the malignancy-associated and drug-
induced forms of the dermatosis.
Mucosal involvement of the mouth, appearing as oral
ulcers, is uncommon in patients with classical Sweet's syn-
drome. However, dermatosis-related oral lesions occurs
more frequently in Sweet's syndrome patients with hema-
tologic disorders [23,26,102,117,203,252]. Similar to
extracutaneous manifestations of Sweet's syndrome
occurring at other sites, the dermatosis-related oral ulcers
typically resolve after initiation of treatment with systemic
corticosteroids [1,2].
Included diseases
Several conditions – including other neutrophilic derma-
toses and leukemia cutis – have been observed to occur
either before, concurrent with, or following the diagnosis
of Sweet's syndrome in patients with this dermatosis.
Therefore, it is reasonable to conclude that the occurrence
of Sweet's syndrome in these individuals may be etiologi-
cally to the development of some of these conditions.
Associated diseases
A bona fide association between Sweet's syndrome proba-
bly exists with the following conditions: cancer (including
both hematologic malignancies and solid tumors) (Figure
8), infections (predominantly of the upper respiratory
tract and the gastrointestinal tract), inflammatory bowel
disease (including both Crohn's disease and ulcerative
colitis), medications (granulocyte-colony stimulating fac-
tor is the most commonly reported drug) and pregnancy
(Table 5). There are also several conditions for which the
association with Sweet's syndrome is possibly bona fide
(Table 6). In addition, the validity of the association
(a and b). Clinical presentation of concurrent Sweet's syn- drome and erythema nodosum Figure 6
(a and b). Clinical presentation of concurrent Sweet's syn-
drome and erythema nodosum. A 30-year-old woman had 
been receiving an oral contraceptive (0.3 mg norgestrel with 
0.3 mg ethinyl estradiol) and an appetite suppressant (105 mg 
phendimetrazine tartrate) during the 5 months before these 
dermatoses appeared. An episode of recurrent herpes labia-
lis involving her right upper lip also began 2 days prior to the 
onset of her skin lesions. Tender, erythematous plaques of 
biopsy-confirmed Sweet's syndrome are shown on the dorsal 
right hand and wrist; the suture indicates the biopsy site (a). 
A tender, erythematous nodule of biopsy confirmed ery-
thema nodosum – which morphologically mimiced subcuta-
neous Sweet's syndrome – is shown on her right pretibial 
region (b). (From [21] Cohen PR, Holder WR, Rapini RP: 
Concurrent Sweet's syndrome and erythema nodosum: a 
report, world literature review and mechanism of pathogen-
esis. J Rheumatol 1992;5:814–820. Copyright 1992, Reprinted 
with permission from the Journal of Rheumatology, Toronto, 
Ontario.)Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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between Sweet's syndrome and many of the conditions
that have been observed in patients with the dermatosis
remains to be established (Table 7) (Figure 9); indeed, the
detection of that condition in an individual with Sweet's
syndrome may merely represent a coincidental occurrence
[1,2,5,11-20,30,36-43,69-126,158-161,164,166,186-
190,195,214,231,236,259-339,401,404,407,409-
411,413,415,417-419,421,424,425,431,433].
Associated neutrophilic dermatoses
Neutrophilic dermatoses of the skin and mucosa demon-
strate a unifying characteristic. They all have an inflamma-
tory infiltrate that consists of mature polymorphonuclear
leukocytes. Although many of these conditions exhibit
similar clinical and pathologic features, the location of the
neutrophilic infiltrate may permit differentiation of these
dermatoses [6,120,416]. Erythema elevatum diutinum
[340], neutrophilic eccrine hidradenitis [6], pyoderma
gangrenosum [231,269,341,342,401], subcorneal pustu-
lar dermatosis [6], and vasculitis [3,192,210,231] are
other neutrophilic dermatoses that have been observed to
occur in patients with Sweet's syndrome. The onset of
Sweet's syndrome may appear prior to, concurrent with,
or following the detection of the additional neutrophilic
dermatoses.
Associated leukemia cutis
Sweet's syndrome may occur in three settings in patients
with hematologic disorders, such as leukemia: (1) a para-
neoplastic syndrome heralding either the initial discovery
of an unsuspected malignancy or the recurrence of a pre-
viously treated cancer; (2) a drug-induced dermatosis sub-
sequent to the patient being treated with either all-trans
retinoic acid, bortezomib, granulocyte-colony stimulating
factor, or imatinib mesylate; or (3) a dermatosis in which
the skin lesions concurrently demonstrate leukemia cutis
[1]. In the latter setting, the individual skin lesions are
characterized by the coincident presence of abnormal
neutrophils (leukemia cutis) and mature polymorphonu-
clear leukocytes (Sweet's syndrome)
[1,70,71,93,109,165,205-211,401,417,425]. The most
frequent hematologic malignancies associated with this
unique presentation of Sweet's syndrome are acute myelo-
cytic leukemia and acute promyelocytic leukemia. Other
hematologic disorders that have been associated with
concurrent Sweet's syndrome and leukemia cutis are
chronic myelogenous leukemia, myelogenous leukemia
(not otherwise specified), and myelodysplastic syndrome
[109].
Several hypotheses have been suggested to explain con-
current Sweet's syndrome and leukemia cutis in the same
lesion. One theory is that the circulating immature mye-
loid precursor cells are innocent bystanders that have
been recruited to the skin as the result of an inflammatory
oncotactic phenomenon stimulated by the Sweet's syn-
drome lesions ("secondary" leukemia cutis)
[165,206,207]. Alternatively, the leukemic cells within the
skin may constitute the bonified incipient presence of a
specific leukemic infiltrate ("primary" leukemia cutis)
[207]. Finally, in patients with "primary" leukemia cutis
who have been treated with this granulocyte-colony stim-
ulating factor, it is possible that the atypical cells of leuke-
mia cutis developed into mature neutrophils of Sweet's
syndrome as a result of granulocyte-colony stimulating
factor therapy-induced differentiation of the sequestered
leukemia cells [205].
Pathological description
The diagnostic criteria for Sweet's syndrome includes a
diffuse infiltrate of mature neutrophils. In addition to the
dense polymorphonuclear cell infiltrate in the upper der-
mis, edema are characteristically present (Figures 8b and
3c). Fragmented neutrophil nuclei (referred to as karyor-
rhexis or leukocytoclasia), swollen endothelial cells, and
(a and b). Histopathology of a Sweet's syndrome lesion  from a patient with concurrent erythema nodosum Figure 7
(a and b). Histopathology of a Sweet's syndrome lesion 
from a patient with concurrent erythema nodosum. Skin 
biopsy from one of the Sweet's syndrome plaques on the 
right dorsal wrist of a woman with concurrent biopsy-con-
firmed Sweet's sydrome and biopsy-confirmed erythema 
nodosum. The characteristic histopathologic features of 
Sweet's syndrome are observed at low (a) and higher (b) 
magnification: papillary dermal edema, swollen endothelial 
cells, and a diffuse infiltrate of predominantly neutrophils 
with leukocytoclasia. There is no evidence of vasculitis 
(hematoxylin and eosin, × 25 (a), × 100 (b)). (From [21] 
Cohen PR, Holder WR, Rapini RP: Concurrent Sweet's syn-
drome and erythema nodosum: a report, world literature 
review and mechanism of pathogenesis. J Rheumatol 
1992;5:814–820. Copyright 1992, Reprinted with permission 
from the Journal of Rheumatology, Toronto, Ontario.)Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
Page 10 of 28
(page number not for citation purposes)
dilated small blood vessels may also be present (Figure 7).
The overlying epidermis is normal and changes of "pri-
mary" leukocytoclastic vasculitis (such as fibrin deposi-
tion or neutrophils within the vessel walls) are usually
absent [1,2,23,167,168].
Since the initial description of 'acute febrile neutrophilic
dermatosis' by Dr. Sweet, the spectrum of pathologic
changes described in cutaneous lesions of Sweet's syn-
drome has expanded. There is variability regarding the
composition of the inflammatory infiltrate and its depth
within the skin. Although the neutrophilic infiltrate is tra-
ditionally found in the dermis, it can also be present in
either the overlying epidermis or the underlying adipose
tissue. Also, in patients with hematologic malignancy-
associated Sweet's syndrome, concurrent leukemia cutis
may be present in the dermatosis-related skin lesions
[3,191].
The predominant cells that comprise the infiltrate in the
dermis of cutaneous Sweet's syndrome lesions are mature
neutrophils. However, eosinophils have been observed
within the dermal infiltrate in the Sweet's syndrome skin
lesions of some patients with either the classical
[11,167,168,195,202-204,212] or the drug-induced
[84,107,110,111] dermatosis. Occasionally, lymphocytes
or histiocytes may also be present in the inflammatory
infiltrate [11,104,167,168,198-200,425].
A unique clinicopathologic subset of 11 Sweet's syndrome
patients has recently been characterized [200,425]. The
patients either presented with or subsequently developed
myelodysplastic syndrome; four of the patients also devel-
oped relapsing polychondritis [5,409,425]. Initially, the
diagnosis of Sweet's syndrome was based on clinical fea-
tures. Surprisingly, the Sweet's syndrome lesions from the
early episodes of the dermatosis in these individuals
showed a dense mononuclear cell infiltrate consisting pre-
dominantly of lymphocytes; histiocytes and atypical
mononuclear cells were also present. However, 24 to 96
months later, sequential biopsies of lesion from recurrent
episodes in these patients revealed neutrophilic dermal
infiltrates typical of Sweet's syndrome [425].
Abnormal or immature myeloid cells have been observed
in Sweet's syndrome lesions. For example, abnormal neu-
trophils (leukemia cutis) – in addition to mature neu-
trophils – comprise the dermal infiltrate in some Sweet's
Table 4: Extracutaneous manifestations of Sweet's syndrome
Bone Acute sterile arthritis, arthralgias, focal aseptic osteitis, pigmented villonodular synovitis, sterile osteomyelitis (chronic 
recurrent multifocal osteomyelitis) [12,32,44,164,212-215].
Central nervous system Acute benign encephalitis, aseptic meningitis, brain SPECT abnormalities, brain stem lesions, cerebrospinal fluid 
abnormalities, computerized axial tomography abnormalities, electroencephalogram abnormalities, encephalitis, Guillain-
Barre syndrome, idiopathic hypertrophic cranial pachymeningitis, idiopathic progressive bilateral sensorineural hearing 
loss, magnetic resonance imaging abnormalities, neurologic symptoms, "neuro-Sweet disease", pareses of central origin, 
polyneuropathy, psychiatric symptoms [33,68,212-229,423].
Ears Tender red nodules and pustules that coalesced to form plaques in the external auditory canal and the tympanic 
membrane [230].
Eyes Blepharitis, conjunctival erythematous lesions with tissue biopsy showing neutrophilic inflammation, conjunctival 
hemorrhage, conjunctivitis, dacryoadenitis, episcleritis, glaucoma, iridocyclitis, iritis, limbal nodules, ocular congestion, 
periocular swelling, peripheral ulcerative keratitis, retinal vasculitis, scleritis, uveitis 
[12,20,26,88,101,185,202,214,229,231-239,421].
Kidneys Mesangiocapillary glomerulonephritis, urinalysis abnormalities (hematuria and proteinuria) [16,17,25,26,73].
Intestines Intestine with extensive and diffuse neutrophilic inflammation, neutrophilic ileal infiltrate, pancolitis (culture-negative) 
[36,203,240,241].
Liver Hepatic portal triad with neutrophilic inflammation, hepatic serum enzyme abnormalities, hepatomegaly 
[12,16,17,20,25,26,212,224,242].
Heart Aortic stenosis (segmental), aortitis (neutrophilic and segmental), cardiomegaly, coronary artery occlusion, heart failure, 
myocardial infiltration by neutrophils, vascular (aorta, bracheocephalic trunk and coronary arteries) dilatation [243-247].
Lung Bronchi (main stem) with red-bordered pustules, bronchi with neutrophilic inflammation, pleural effusion showing 
abundant neutrophils without microorganisms, progressive pharyngeal mucosal infiltration and edema resulting in upper-
airway obstruction, and chest roentgenogram abnormalities: corticosteroid-responsive culture-negative infiltratives, 
pulmonary tissue with neutrophilic inflammation [17,20,73,101,138,139,165,205,212,246-251,434].
Mouth Aphthous-like superficial lesions (buccal mucosa, tongue), bullae and vesicles (hemorrhagic: labial and gingival mucosa), 
gingival hyperplasia, necrotizing ulcerative periodontitis, nodules (necrotic: labial mucosa), papules (macerated: palate and 
tongue), pustules (individual and grouped: palate and pharynx), swelling (tongue), ulcers (buccal mucosa and palate) 
[26,75,102,117,203,249,252-254].
Muscles Magnetic resonance imaging (T1-weighted and T2-weighted) abnormalities: high signal intensities due to myositis and 
fasciitis, myalgias (in up to half of the patients with idiopathic Sweet's syndrome), myositis (neutrophilic), tendinitis, 
tenosynovitis [73,75,244,255-257].
Spleen Splenomegaly [212].
Source [1]: Adapted with permission from Cohen PR, Kurzrock R: Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 
2003;42:761–778. Copyright 2003, Reprinted with permission from the International Society of Dermatology, Blackwell Publishing Ltd, Oxford, United Kingdom.Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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syndrome patients with hematologic disorders
[1,70,71,93,109,165,205-211,401,417]. Recently, a "his-
tiocytoid" pathologic variant of Sweet's syndrome has
been described; it is characterized by an infiltrate mainly
composed of immature myeloid cells which have been
misinterpreted as histiocytes (macrophages) [201].
The inflammatory infiltrate in Sweet's syndrome is usually
located in the papillary and upper reticular dermis. How-
ever, neutrophils can also be present in the epidermis
[17,197] or adipose tissue. For example, exocytosis of
neutrophils into the overlying epidermis has been
observed as either neutrophilic spongiotic vesicles [194]
or subcorneal pustules [12,80,167,195,196]. The condi-
tion is referred to as "subcutaneous Sweet's syndrome"
when the neutrophils are located either entirely or only
partially in the subcutaneous fat [4,8,12,17,99,119,164-
184,397,399,417].
Subcutaneous Sweet's syndrome can involve either the
adipose tissue alone or both the dermis and the subcuta-
neous fat [1,4,401]. Within the subcutaneous fat, the neu-
trophilic infiltrate is present in the lobules 166,167,171-
173,399,401,417], the septae [167,397], or both
[167,174-177]. The presence of subcutaneous neu-
trophilic inflammation in Sweet's syndrome lesions may
be a more common finding in patients with either an
associated hematologic dyscrasia
[99,165,170,174,177,178,183,184,401,417] or solid
tumor [397,399].
Cutaneous lesions of subcutaneous Sweet's syndrome typ-
ically present as tender erythematous subepidermal nod-
ules on the extremities. They are morphologically similar
in appearance to erythema nodosum [431]. Therefore, a
biopsy of one or more new nodules may be necessary to
establish the correct diagnosis – even in a patient with his-
tology – confirmed Sweet's syndrome – since Sweet's syn-
drome can develop concurrently or sequentially with
erythema nodosum [21,405].
The neutrophils are typically located in the papillary and
upper reticular dermis as a dense and diffusely distributed
infiltrate in Sweet's syndrome lesions. However, in some
Sweet's syndrome lesions, the neutrophils have been
observed to be perivascular and exhibiting pathologic
changes consistent with leukocytoclastic vasculitis
[192,193,396,401,410,428]. In these lesions of Sweet's
syndrome, the vascular changes are considered to be those
of a "secondary" leukocytoclastic vasculitis occurring as
an epiphenomenon and not representative of a "primary"
vasculitis [3]. However, some authors have introduced an
alternative hypothesis: that Sweet's syndrome be regarded
as a variant of leukocytoclastic vasculitis [428].
Table 6: Sweet's syndrome and possibly associated conditions
Behcet's disease [272]
Erythema nodosum [17,30,186,187,190,214,236,264,266,273-276,405,415]
Relapsing polychondritis [5,20,195,277-280,409,425]
Rheumatoid arthritis [12,16,20,231]
Sarcoidosis [18,188,274,281-283,409,413]
Thyroid disease: Grave's disease [117,284,285] and Hashimoto's thyroiditis [12,286]
Source [1]: Adapted with permission from Cohen PR, Kurzrock R: Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 
2003;42:761–778. Copyright 2003, Reprinted with permission from the International Society of Dermatology, Blackwell Publishing Ltd, Oxford, United 
Kingdom.
Table 5: Sweet's syndrome and probably associated conditions
Cancer Hematologic malignancies (most commonly acute myelogenous 
leukemia) and solid tumors (most commonly carcinomas of the 
genitourinary organs, breast, and gastrointestinal tract) [15]
Infections [12,16,17,19,20,125,126,166,186,259] Most commonly of the upper respiratory tract (streptococcosis) 
[16,17,20,186] and the gastrointestinal tract (salmonellosis [19,166] and 
yersiniosis [12])
Inflammatory bowel disease [260] Crohn's disease [12,16,17,20,30,115,164,187,261-267,411] and 
ulcerative colitis [12,16-18,20,30,214,268,269]
Medications Most commonly granulocyte colony-stimulating factor 
[11,13,17,39,41,69-124,404,417]
Pregnancy [12,16,30,270,271,410]
Source [1]: Adapted with permission from Cohen PR, Kurzrock R: Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 
2003;42:761–778. Copyright 2003, Reprinted with permission from the International Society of Dermatology, Blackwell Publishing Ltd, Oxford, United 
Kingdom.Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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Pathologic findings of Sweet's syndrome can also occur in
extracutaneous sites. They often present as sterile neu-
trophilic inflammation in the involved organ. These
changes have been described in the bones, intestines,
liver, aorta, lungs, and muscles of patients with Sweet's
syndrome.
Etiology
The pathogenesis of Sweet's syndrome remains to be
definitively determined. Indeed, it may be multifactorial
and many etiologies – not necessarily mutually exclusive
– have been postulated. The accompanying fever and
peripheral leukocytosis suggest a septic process. Since
most patients with classic Sweet's syndrome have a febrile
Table 7: Conditions for which the validity of their association in Sweet's syndrome patients remains to be established
Alpha 1-antitrypsin deficiency [42]
Anti-factor VIII inhibitor [287]
Antiphospholipid syndrome [1]
Aortitis (Takayasu's arteritis) [286,288]
Aplastic anemia [39,99]
Autoimmune disorders: autoimmune thrombocytopenic purpura [401], connective tissue disease (undifferentiated) [401], dermatomyositis [20], 
lupus erythematosus (subacute [289] and systemic [119,290,401]), pemphigus vulgaris [291] and Sjogren's syndrome [12,17,265,433]
Bronchiolitis obliterans and organizing pneumonia [292-294]
Chemical fertilizer [158]
Chronic fatigue syndrome [295]
Cirrhosis (cryptogenic) [30]
Cholelithiasis [421]
Common bile duct and intrahepatic duct stones [19]
Congenital dyserythropoietic anemia [18]
Congenital neutropenia (Kostmann's syndrome) [97]
Cutis laxa (acquired, Marshall syndrome) [38,42,245,246]
Dressler's syndrome (postmyocardial infarction syndrome) [17]
Eosinophilic granuloma [19]
Fanconi anemia [36,241]
Glycogen storage disease (Type Ib) [41]
Granuloma annulare [296]
IgA nephropathy (Berger's disease) [97]
Immunizing agent (BCG vaccination and flu) [17,297,298,419]
Immunodeficiency diseases: chronic granulomatous disease [37,299,300], complement deficiency [30], human immunodeficiency virus infection 
[98,254,302], and primary T-cell immunodeficiency disease [43,303])
Infections: Anaplasma phagocytophilum [304], bartholinitis [17], bronchitis [17], Capnocytophaga canimorsus [305], chlamydia [306-308], cholangitis 
[19], cholecystitis [12], coccidioidomycosis [309], cytomegalovirus [1,310,311], Entamoeba histolytica [214], Epstein-Barr virus [1], Francisella 
tularensis [312], Helicobacter pylori [313], hepatitis (acute hepatitis B [314], autoimmune [251], cholestatic [30], chronic active [315], hepatitis C 
[161], and prior hepatitis A [1]), herpes simplex [316,317], herpes zoster [119], histoplasmosis [259], human immunodeficiency virus [98,254,302], 
leprosy [19], lymphadenitis (not otherwise specified [318,319] and subacute necrotizing [212,318]), mycobacteria (nontuberculous) 
[19,212,316,320-322,401], otitis media [12,17], pancreatitis [30], Pasteurella multocida bronchitis [323], Penicillium species [401], Pneumocystis carinii 
pneumonia [324], pyelonephritis [12], Salmonella (group D cervical lymphadenitis) [401], Staphylococcus aureus [44,326,431], Staphylococcus 
epidermidis (methicillin resistant) [407], subacute bacterial endocarditis [327], tonsillitis [12,17,19], toxoplasmosis [328], Trichophyton rubrum [418], 
tuberculosis [17,329,330], ureaplasmosis [331], urinary tract [17,20], and vulvovaginitis [12,20]
Malabsorption [30]
Mid-dermal elastolysis [332]
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) [333]
Postoperative (pneumonectomy) [334]
Psoriasis vulgaris [16]
Rhinosinusitis [335]
SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, and osteomyelitis) [424]
Still's disease [336]
Thermal injury [160]
Transient acantholytic dermatosis (Grover's disease) [337]
Ureter obstruction [338]
Urticaria (chronic) [17]
Urticaria pigmentosa [12]
Welding burns [339]
Source [1]: Adapted with permission from Cohen PR, Kurzrock R: Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 
2003;42:761–778. Copyright 2003, Reprinted with permission from the International Society of Dermatology, Blackwell Publishing Ltd, Oxford, United 
Kingdom.Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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upper respiratory tract infection or tonsillitis that precedes
their skin lesions by 1 to 3 weeks, a bacterial infection may
have a causative role. Also, the manifestations of Sweet's
syndrome improve with systemic antibiotics in some of
the patients with dermatosis-associated culture-confirmed
and serology-confirmed Yersinia enterolitica intestinal
infection [2,77,125-127].
A hypersensitivity reaction to an eliciting bacterial, viral,
or tumor antigen may promote the development of
Sweet's syndrome. This concept is suggested by the
appearance, histopathology and course of the Sweet's syn-
drome skin lesions. This hypothesis is also supported by
the prompt response of both the symptoms and the
lesions to corticosteroids [2,127].
Circulating autoantibodies, cytokines, dermal dendro-
cytes, human leukocyte antigen serotypes, immune com-
plexes, and leukotactic mechanisms have all been
postulated to contribute to the pathogenesis of Sweet's
syndrome. However, complement does not appear to be
essential to the disease process. Antibodies to neutrophilic
cytoplasmic antigens have been demonstrated in some
Sweet's syndrome patients. Yet, their role in the pathogen-
esis of this dermatosis has not been established and they
are likely to represent an epiphenomenon [2].
The effects of cytokines – either directly or indirectly or
both – have an etiologic role in the development of
Sweet's syndrome symptoms and lesions [2,21-23]. Gran-
ulocyte-colony stimulating factor, granulocyte macro-
phage colony stimulating factor, interferon-gamma,
interleukin-1, interleukin-3, interleukin-6, and inter-
leukin-8 are potential cytokine candidates
[2,13,21,23,44,128-132,397,398]. Recently, a healthy
woman donor for peripheral blood stem cell harvest was
observed to develop granulocyte-colony stimulating fac-
tor-induced Sweet's syndrome which appeared four days
after commencing granulocyte-colony stimulating factor
at a dose of 10 micrograms per kilogram per day [398].
Tumor-associated production of granulocyte-colony stim-
ulating factor may be involved in the development of
Sweet's syndrome in patients with dermatosis-related
malignancies. Production of granulocyte-colony stimulat-
ing factor and marked leukocytosis have been demon-
strated by various malignant tumors.
(a and b) Figure 9
(a and b). Recurrent, oral corticosteroid-responsive, 
Sweet's syndrome lesions. A 46-year-old Indian woman with 
oral corticosteroid-responsive, tender erythematous, biopsy-
confirmed plaques of recurrent Sweet's syndrome on the 
posterior neck (a) and right arm (b). Her laboratory evalua-
tion was significant for the elevation of the erythrocyte sedi-
mentation rate, liver function tests [serum glutamic-
oxaloacetic transaminase (SGOT), serum glutamic-pyruvic 
transaminase (SGPT), and lactate dehydrogenase (LDH)], 
cytomegalovirus immunoglobulin G (IgG) antibody (consist-
ent with previous exposure), hepatitis A IgG antibody (con-
sistent with previous infection), and Epstein-Barr virus capsid 
IgG antibody (consistent with recent or past infection). 
(From [1] Cohen PR, Kurzrock R: Sweet's syndrome revis-
ited: a review of disease concepts. Int J Dermatol 
2003;42:761–778. Copyright 2003, Reprinted with permission 
from the International Society of Dermatology, Blackwell Publish-
ing, Oxford, United Kingdom.)
(a and b). Malignancy-associated Sweet's syndrome in a  woman with dermatosis-related laryngeal carcinoma Figure 8
(a and b). Malignancy-associated Sweet's syndrome in a 
woman with dermatosis-related laryngeal carcinoma. Solid 
tumor-associated Sweet's syndrome in a 69-year-old woman 
in whom a workup after the appearance of Sweet's syndrome 
lesions revealed an unsuspected recurrent squamous cell car-
cinoma of the larynx. A tender, erythematous-based, vesicu-
lar-appearing nodule of Sweet's syndrome with central 
ulceration and crust located proximally on the dorsum of the 
right second digit is shown (a). The histologic features of the 
Sweet's syndrome lesion revealed a neutrophilic dermatosis; 
the papillary dermis was edematous and contained a dense 
infiltrate of neutrophils (b) (hematoxylin and eosin, × 50). 
(From [362] Cohen PR, Holder WR, Tucker SB, Kono S, 
Kurzrock R: Sweet's syndrome in patients with solid tumors. 
Cancer 1993;72:2723–2731. Copyright 1993, Reprinted with 
permission from John Wiley & Sons, Inc., Hoboken, New Jersey.)Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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Immunohistiochemical studies showed staining for gran-
ulocyte-colony stimulating factor in the tumor cells and
surrounding matrix of an intrahepatic cholangiocarci-
noma which had been resected from a woman whose
Sweet's syndrome was associated with this cancer.
Although the level of serum granuocyte-colony stimulat-
ing factor was not abnormally elevated, the detection of
granulocyte-colony stimulating factor in the tumor sug-
gests the possiblity that tumors capable of producing
granulocyte-colony stimulating factor might cause Sweet's
syndrome in these oncology patients [397].
Another example supporting the role of cytokines in the
pathogenesis of Sweet's syndrome is a patient with myel-
odysplastic syndrome-associated (non-granulocyte-col-
ony stimulating factor-induced) Sweet's syndrome in
whom elevated serum levels of granulocyte-colony stimu-
lating factor and interleukin-6 were detected [128]. Also,
in an infant with classical Sweet's syndrome, detectable
levels of intra-articular synovial fluid granulocyte macro-
phage-colony stimulating factor were observed [44]. A
recent study comparing patients with active and inactive
Sweet's syndrome demonstrated significantly higher lev-
els of serum granulocyte-colony stimulating factor in indi-
viduals whose dermatosis was active than in patients
whose Sweet's syndrome was inactive [129].
Immunohistochemical evaluation of the epidermis of
Sweet's syndrome lesions suggests the importance of
interleukins as a potential cytokine mediator in Sweet's
syndrome. Significantly elevated levels of helper T-cell
type 1 cytokines (interleukin-2 and interferon-gamma)
and normal levels of a helper T-cell type 2 cytokine (inter-
leukin-4) were observed in the immunohistochemical
studies of Sweet's syndrome patients' serum [130].
Decreased epidermal staining for interleukin-1 and inter-
leukin-6 were noted in other immunohistochemical stud-
ies; the investigators postulated that these findings were
due to the release of these cytokines into the dermis [131].
In summary, granulocyte-colony stimulating factor, gran-
ulocyte macrophage colony stimulating factor, interferon-
gamma, interleukin-1, interleukin-3, interleukin-6, and
interleukin-8 are potential cytokine candidates in the
pathogenesis of Sweet's syndrome [2,13,21-23,44,128-
132].
The possibility that Sweet's syndrome, when associated
with neutrophil monoclonality, represents a form of
indolent, localized cutaneous neutrophilic dyscrasia has
recently been postulated. An X-inactivation assay to detect
clonal restriction of neutrophils, based on the human
androgen receptor (HUMARA) gene, was performed on
Sweet's syndrome skin biopsy specimens from four
patients with acute myelogenous leukemia and two
patients without underlying hematologic dyscrasia when
the biopsies were obtained. Clonal restriction of the neu-
trophil infiltrate was found in two of the patients with
acute myelogenous leukemia; the other two patients were
homozygous for the HUMARA gene, precluding analysis.
Both control patients had clonal restricted infiltrates
within their skin lesions; subsequent investigation
revealed unexplained neutropenia with a bone marrow
biopsy interpreted as being within normal limits and no
further features to suggest a definitive myeloproliferative
disorder. These findings demonstrated that clonality of
the neutrophilic infiltrate in Sweet's syndrome skin
lesions is not exclusively restricted to patients with an
established myeloproliferative disease. The significance of
the clonal neutrophilic infiltrate in Sweet's syndrome
patients without an underlying myeloid dysplasia
remains to be determined; however, the investigators
speculated that it may have some implications regarding
the pathogenesis of sterile neutrophilic infiltrates [429].
Diagnostic methods
Lesional skin biopsy
A lesional skin biopsy for routine histopathologic evalua-
tion is a useful procedure to confirm a clinically suspected
diagnosis of Sweet's syndrome. Pathologic features of
Sweet's syndrome, such as the diffuse inflammatory infil-
trate of neutrophils in the dermis, subcutaneous fat, or
both can also be observed in cutaneous lesions caused by
an infectious agent. Therefore, it may also be prudent to
also submit lesional tissue for bacterial, fungal, mycobac-
terial, and possibly viral cultures [1,2].
Laboratory evaluation
The most consistent laboratory abnormalties in patients
with Sweet's syndrome are peripheral leukocytosis with
neutrophilia and an elevated erythrocyte sedimentation
rate [23]. However, an elevated white blood cell count is
not always observed in all patients with biopsy-confirmed
Sweet's syndrome [26]. For example, some of the patients
with malignancy-associated Sweet's syndrome may have
either anemia, neutropenia, and/or abnormal platelet
counts.
Extracutaneous manifestations of Sweet's syndrome may
result in other laboratory abnormalities. Abnormalites
may be found on brain SPECTs, computerized axial tom-
ography, electroencephalograms, magnetic resonance
imaging and cerebrospinal fluid analysis in patients with
central nervous system involvement. Urinalysis abnor-
malities (hematuria and proteinuria) may be observed in
patients with dermatosis-related kidney involvement.
Hepatic serum enzyme elevation may be present in
patients with Sweet's syndrome-associated liver involv-
ment. Pleural effusions and corticosteroid-responsive cul-
ture-negative infiltrates may be present on chest
roentgenograms in patients with Sweet's syndrome whoOrphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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have extracutaneous manifestations that involve their
lungs [2,343].
Laboratory evaluation should include a complete blood
cell count with leukocyte differential and platelet count.
Evaluation of acute phase reactants (such as the erythro-
cyte sedimentation rate or C-reactive protein), serum
chemistries (evaluating hepatic function and renal func-
tion) and a urinalysis should also be performed. It may
also be reasonable to perform a serologic evaluation for
antistreptolysin-O antibody, rheumatoid factor, and thy-
roid function since streptococcal infection, rheumatoid
arthritis, and thyroid disease have been observed to have
either a probably or possible bona fide association with
the dermatosis [1,2].
Recommendations for the initial malignancy workup in
newly diagnosed Sweet's syndrome patients without a
prior cancer were proposed by Cohen and Kurzrock [15]
in 1993. Their recommendations were based upon the
neoplasms that had concurrently or subsequently been
discovered in previously cancer-free Sweet's syndrome
patients and the age-related recommendations by the
American Cancer Society for the early detection of cancer
in asymptomatic persons [406]. They recommended: (1)
a detailed medical history; (2) a complete physical exam-
ination, including: (a) examination of the thyroid, lymph
nodes, oral cavity, and skin; (b) digital rectal examination;
(c) breast, ovary, and pelvic examination in women; and
(d) prostate and testicle examination in men; (3) labora-
tory evaluation: (a) carcinoembryonic antigen level; (b)
complete blood cell count with leukocyte differential and
platelet count; (c) pap test in women; (c) serum chemis-
tries; (d) stool guaiac slide test; (e) urinalysis; and (f)
urine culture; and (4) other screening tests: (a) chest
roentgenograms; (b) endometrial tissue sampling in
either menopausal women or women with a history of
abnormal uterine bleeding, estrogen therapy, failure to
ovulate, infertility, or obesity; and (c) sigmoidoscopy in
patients over 50 years of age. They also suggested that it
was reasonable to check a complete blood cell count with
leukocyte differential and platelet count every 6 to 12
months since the intial appearance of dermatosis-related
skin lesions preceded the diagnosis of a Sweet's syn-
drome-associated hematologic malignancy by as long as
11 years [2,15].
Differential diagnosis
Clinical differential diagnosis
There are several mucocutaneous and systemic disorders
whose dermatologic manifestations can morpholocally
mimic those of Sweet's sydrome. These disorders consist
of not only cutaneous conditions and systemic diseases,
but also infectious and inflammatory disorders, neoplas-
tic conditions, reactive erythemas, and vasculitis (Figure
10). The clinical differential diagnosis of Sweet's syn-
drome is listed in Table
8[2,15,23,148,165,194,202,220,344,345,400,412,422].
Histologic differential diagnosis
The histologic differential diagnosis of Sweet's syndrome
includes conditions microscopically characterized by
either neutrophilic dermatosis or neutrophilic panniculi-
tis (Table 9) [2-4,6,12,193,346-353]. Neutrophilic derm-
atoses include abscess or cellulitis, bowel (intestinal)
bypass syndrome, erythema elevatum diutinum, granu-
loma faciale, halogenoderma, leukocytoclastic vasculitis,
neutrophilic eccrine hidradenitis, pyoderma gangreno-
sum, and rheumatoid neutrophilic dermatitis. Culture of
lesional tissue for bacteria, fungi, and mycobacteria
should be considered to rule out infection since the path-
ologic changes associated with Sweet's syndrome are sim-
ilar to those observed in an abscess or cellulitis [23].
Table 8: Clinical differential diagnosis of Sweet's syndrome
Cutaneous conditions Acral erythema
Drug eruptions
Halogenoderma
Rosacea fulminans
Infectious and inflammatory disorders Bacterial sepsis
Cellulitis
Erysipelas
Herpes simplex virus
Herpes zoster virus
Leprosy
Lymphangiitis
Panniculitis
Pyoderma gangrenosum
Syphilis
Systemic mycoses
Thrombophlebitis
Tuberculosis
Viral exanthem
Neoplastic conditions Chloroma
Leukemia cutis
Lymphoma
Metastatic tumor
Reactive erythemas Erythema multiforme
Erythema nodosum
Urticaria
Systemic diseases Behcet's disease
Bowel bypass syndrome
Dermatomyositis
Familial Mediterranean fever
Lupus erythematosus
Vasculitis Erythema elevatum diutinum
Granuloma faciale
Leukocytoclastic vasculitis
Periarteritis nodosa
Source [15]: Adapted with permission from Cohen PR, Kurzrock R: 
Sweet's syndrome and cancer. Clin Dermatol 1993;11:149–157. 
Copyright 1993, Reprinted with permission from Elsevier Ltd, Oxford, 
United Kingdom.Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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Leukemia cutis can occur concurrently with Sweet's syn-
drome. It can also mimic the dermal changes of Sweet's
syndrome. However, in contrast to the mature polymor-
phonuclear neutrophils found in Sweet's syndrome, the
dermal infiltrate in leukemia cutis consists of malignant
immature leukocytes [354].
Subcutaneous Sweet's syndrome lesions may have patho-
logic changes in the adipose tissue that can be found in
either the lobules, the septae, or both. Hence, the adipose
tissue changes of subcutaneous Sweet's syndrome are sim-
ilar to those of other conditions characterized by a neu-
trophilic lobular and/or septal panniculitis. Therefore,
alpha 1-antitrypsin deficiency, factitial panniculitis, infec-
tion, leukocytoclastic vasculitis, pancreatitis, and rheuma-
toid arthritis should be considered and ruled out [2,4].
Management
Sweet's syndrome lesions, if untreated, can remain for
weeks to months. However, without any therapeutic inter-
vention, the dermatosis-related symptoms and cutaneous
lesions eventually resolved in some patients with classical
Sweet's syndrome [10]. Cure or remission of the dermato-
sis-related cancer in patients with malignancy-associated
Sweet's syndrome is occasionally followed by resolution
of the individual's Sweet's syndrome. And, in patients
with drug-induced Sweet's syndrome, spontaneous
improvement and subsequent clearing of the syndrome
occurs after stopping the associated medication. Surgical
intervention has also occasionally promoted resolution of
the patient's Sweet's syndrome when the dermatosis was
associated with therapy amendable tonsillitis, solid
tumors, or renal failure.
Topical or intralesional corticosteroids
Topical or intralesional corticosteroids can be used to
treat patients who have a small number of localized
Sweet's syndrome lesions as either monotherapy or con-
currently with another therapy [1,2,7]. High potency top-
ical corticosteroids (such as 0.05% clobetasol propionate)
in either a cream base, an ointment base, a gel base, or a
foam base can be applied to the lesions [13,19-
21,30,234,362-365]. Individual lesions have improved
following a single injection or multiple intralesional treat-
(a and b). Sweet's syndrome with lesions distributed in a sporotrichoid pattern Figure 10
(a and b). Sweet's syndrome with lesions distributed in a sporotrichoid pattern. A 53-year-old Hispanic woman presented to 
the emergency room with a recent episode of a "sore throat," fever, and a 2-day history of a swollen, tender left wrist accom-
panied by erythema that was beginning to extend proximally; a bacterial cellulitis was clinically suspected and she was started 
on oral antibiotics: double-strength trimethoprim-sulfamethoxazole twice daily and 400 mg of ofloxacin twice daily. She was 
initially seen in the dermatology clinic 9 days later; she was still febrile and her original lesion had developed into a painful larger 
pseudovesicular nodule on the radial side of her left wrist. In addition, distal (a) and closer (b) views show a smaller red dermal 
nodule (between arrows) that appeared on her left arm proximal to the original lesion. The clinical differential diagnosis 
included infections whose lesions demonstrated a sporotrichoid pattern (sporotrichosis and atypical mycobacterial infection) 
and Sweet's syndrome. Biopsies for microscopic and culture evaluation were performed. In addition to her antibiotics, the 
patient was started on oral saturated solution of potassium iodide (3 drops 3 times each day and increased by 1 drop each day 
to a final dose of 10 drops 3 times each day). The hematoxylin and eosin-stained sections from her biopsy showed a neu-
trophilic dermatosis; the bacterial, mycobacterial, and fungal cultures were negative for organisms. Within a few days after ini-
tiating treatment with potassium iodide, her symptoms resolved and her skin lesions began to improve. (From [23] Cohen PR, 
Kurzrock R: Sweet's syndrome: a neutrophilic dermatosis classically associated with acute onset and fever. Clin Dermatol 
2000;18:265–282. Copyright 2000, Reprinted with permission from Elsevier Ltd, Oxford, United Kingdom.)Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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ments with triamcinolone acetonide when used at a dose
ranging from 3 mg/ml to 10 mg/ml [362,366,367].
First-line systemic agents
Systemic corticosteroids are the therapeutic mainstay for
Sweet's syndrome. Other first-line systemic treatments for
Sweet's syndrome are potassium iodide and colchicine
(Table 10)
[10,12,17,20,23,30,49,70,143,184,198,203,221,223,231
,240,245,250,259,261,281,284,294,296,329,359-
363,368-384,397,410].
Corticosteroids
Systemic corticosteroids are the "gold standard" of ther-
apy for Sweet's syndrome
[7,8,10,12,16,17,19,20,23,36,49,50,70,184,223,233,240
,250,284,358-361]. Dermatosis-associated symptoms
improve promptly after treatment has been started and
the cutaneous lesions resolve subsequently. Systemic cor-
ticosteroid therapy often begins with 1 mg/kg/day of
prednisone as a single oral morning dose. Usually, the
dose can be tapered to 10 mg/day within 4 to 6 weeks.
However, some patients may require treatment for 2 to 3
months.
Table 10: First-line systemic agents for Sweet's syndrome
Corticosteroids
Prednisone 1 mg/kg/day (usually ranging from 30 mg to 60 mg) as a single oral morning dose. Within 4 to 6 weeks, 
taper dose to 10 mg/day; however, some patients may require 2 to 3 months of treatment or 
intravenous therapy [10,23,49,250]
Methylprednisolone sodium succinate Intravenously administered (up to 1000 mg per day) over 1 or more hours, daily for 3 to 5 days. This is 
followed by a tapering oral dose of corticosteroid or another immunosuppressant agent 
[70,184,223,240,359-361].
Potassium iodide Administered orally as 300 mg enteric-coated tablets, 3 times each day (for a daily dose of 900 mg) or as 
a saturated solution (1 gram/ml of water) of potassium iodide (SSKI, also referred to as Lugol's solution), 
beginning at a dose of 3 drops 3 times each day (9 drops/day = 450 mg per day) and increasing by 1 drop 
3 times per day, typically to a final dose of 21 drops/day (1050 mg) to 30 drops/day (1500 mg) 
[17,20,23,143,198,361-363,368-374,397].a
Colchicine Administered orally at a dose of 0.5 mg three times each day (for a daily dose of 1.5 mg) 
[20,30,281,284,329,360,371,373,375-377,410].
a1 drop = 0.05 ml (or 50 mg when the concentration of potassium iodide is 1000 mg/ml) when a "standard" medicine dropper (which dispenses 20 
drops per ml) is used.
Source [1]: Adapted with permission from Cohen PR, Kurzrock R: Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 
2003;42:761–778. Copyright 2003, Reprinted with permission from the International Society of Dermatology, Blackwell Publishing Ltd, Oxford, United Kingdom.
Table 9: Histologic differential diagnosis of Sweet's syndrome
Abscess/cellulitis Positive culture for infectious agent
Bowel (intestinal) bypass syndrome History of jejunal-ileal bypass surgery for morbid obesity
Erythema elevatum diutinum Erythematous asymptomatic plaques often located on the dorsal hands and elbows; younger lesions have 
microscopic features of leukocytoclastic vasculitis, whereas older lesions have dermal fibrosis and mucin
Granuloma faciale Yellow to red to brown indurated asymptomatic facial plaques; there is a grenz zone of normal papillary 
dermis beneath which there is a dense diffuse inflammatory infiltrate of predominantly neutrophils (with 
microscopic features of leukocytoclastic vasculitis) and frequently numerous eosinophils
Halogenoderma Neutrophilic dermal infiltrate with necrosis and pseudoepitheliomatous hyperplasia with intraepidermal 
abscesses; history of ingestion of bromides (leg lesions), iodides (facial lesions), or topical fluoride gel to teeth 
during tumor radiation therapy to face
Leukemia cutis Dermal infiltrate consists of immature neutrophils
Leukocytoclastic vasculitis Vessel wall destruction – extravasated erythrocytes, fibrinoid necrosis of vessel walls, karyorrhexis, and 
neutrophils in the vessel wall
Lobular neutrophilic panniculitides In addition to subcutaneous Sweet's syndrome, these include alpha 1-antitrypsin deficiency syndrome, factitial 
panniculitis (secondary to the presence of iatrogenic or self-induced foreign bodies), infectious panniculitis 
(secondary to either a bacterial, fungal, mycobacterial, or protozoan organism), pancreatic panniculitis, 
rheumatoid arthritis-associated panniculitis
Neutrophilic eccrine hidradenitis Neutrophils around eccrine glands, often in patients with acute myelogenous leukemia receiving induction 
chemotherapy
Pyoderma gangrenosum Painful ulcer with overhanging, undermined violaceous edges
Rheumatoid neutrophilic dermatitis History of rheumatoid arthritis, nodules, and plaques
Sweet's syndrome Acute onset, fever, neutrophilia, and painful plaques
Source [346]: Adapted with permission from Cohen PR: Paraneoplastic dermatopathology: cutaneous paraneoplastic syndromes. Adv Dermatol 
1995;11:215–252. Copyright 1995, Reprinted with permission from Elsevier Ltd, Oxford, United Kingdom.Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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Intravenous corticosteroid therapy may be necessary in
those Sweet's syndrome patients whose dermatosis has
been refractory to other treatments [400]. Daily pulse
intravenous methylprednisolone sodium succinate (at a
dose of up to 1000 mg/day) over 1 or more hours for 3 to
5 days can be given. Upon conclusion of the course of
intravenous treatment, either a tapering oral dose of corti-
costeroid or another immunosuppressant agent usually
follows.
Potassium iodide
Horio  et al [143] originally described the dramatic
improvement in patients with Sweet's syndrome who
were treated with potassium iodide in 1980. He con-
firmed his earlier observations with a larger study in 1983
[368]. Subsequently, several other investigators have also
observed similar improvement when using potassium
iodide to treat patients with Sweet's syndrome. Vasculitis
and hypothyroidism are potential drug-induced side
effects of potassium iodide [385].
After the initiation of potassium iodide therapy, symp-
toms of the dermatosis typically resolve within 1 to 2 days
and skin lesions subside within 3 to 5 days. Potassium
iodide, when available as a 300 mg enteric-coated tablet,
can be administered orally 3 times each day (for a total
daily dose of 900 mg). Alternatively, when the drug is
available as a saturated solution (1 gram/ml of water) of
potassium iodide (SSKI, which is also referred to as
Lugol's solution), it is initially given at a dose of 3 drops 3
times each day. When a "standard" medicine dropper
(which dispenses 20 drops per ml) is used, 1 drop equals
0.05 ml (or 50 mg when the concentration of potassium
iodide is 1000 mg/ml). Therefore, the initial dose is 9
drops per day which equals 450 mg of potassium iodide
per day. The dose is increased by 1drop 3 times each day,
typically to a final dose between 21 drops per day (1050
mg) to 30 drops per day (1500 mg).
Colchicine
The efficacy of colchicine for Sweet's syndrome was ini-
tially reported by Suehisa and Tagami [373] in 1981. Two
years later, in 1983, Suehisa et al [375] reported 3 addi-
tional patients with Sweet's syndrome who were success-
fully treated with colchicine. Colchicine may cause
gastrointestinal symptoms such as diarrhea, abdominal
pain, nausea and vomiting. These potential adverse effects
from colchicine may improve after lowering the daily
dose of the drug [2].
Several larger studies have subsequently confirmed that
colchicine is an effective agent for the successful manage-
ment of patients with Sweet's syndrome. For example,
Maillard et al [329] presented 20 patients with Sweet's
syndrome of whom 90% (18 individual) responded to
colchicine therapy: fever resolved within 2 to 3 days, skin
lesions attenuated within 2 to 5 days, arthralgia disap-
peared within 2 to 4 days, and leukocytosis normalized
within 8 to 14 days. Similar to earlier studies, the starting
dose of colchicine was 0.5 mg orally 3 times each day (for
a total daily dose of 1.5 mg); treatment ranged from 10 to
21 days (mean = 15 days).
Second-line systemic agents
Second-line agents for treating Sweet's syndrome include
indomethacin, clofazimine, cyclosporin, and dapsone
(Table 11)
[1,12,17,20,30,203,221,231,245,259,261,284,294,296,3
72,378-384,421]. All of these agents have been used as
monotherapy either in the initial management of the
patient or after first-line therapies have failed. In addition,
cyclosporine and dapsone have been used in combination
therapy either with other drugs or as a corticosteroid-spar-
ing agent [1,2,7,303,421].
Indomethacin and clofazimine
Indomethacin and clofazimine have each been described
in individual case reports and a single larger study to be
effective for the management of patients with Sweet's syn-
dome. In 1997, Jeanfils et al [261] reported the therapeu-
tic efficacy for 17 of the 18 patients with Sweet's syndrome
who received indomethacin as first-line monotherapy: an
oral daily dose of 150 mg for 7 days and then 100 mg per
day for 14 days. Von den Driesch [12] reported "almost
complete remission" in 6 patients who were treated with
clofazimine. The patients had chronic and relapsing
Sweet's syndrome and had previously been unsuccessfully
treated with methylprednisolone; they received an oral
Table 11: Second-line systemic agents for Sweet's syndrome
Indomethacin Administered at a oral daily dose of 150 mg for 7 days, and then 100 mg per day for 14 days [259,261,284,378].
Clofazimine Administered orally at a daily dose of 200 mg for 4 weeks, and then 100 mg per day for 4 weeks [12,296,379].
Cyclosporin As monotherapy or as a second-line agent (after failure of first-line therapy or as a corticosteroid-sparing agent) 
[12,30,231,294,380,381]. Initial oral daily dose ranged from 2 mg/kg/d [380] to 4 mg/kg/d [231] to 10 mg/kg/d [12,381]; in the 
latter patient, from the 11th day the dose was reduced by 2 mg/kg/d every 2 days and discontinued on day 21 [12,381].
Dapsone As either monotherapy or in combination therapy. Initial oral dose ranged from 100 mg per day to 200 mg per day; the latter dose 
was either administered as a single dose or divided into 2 equal doses [17,20,30,203,221,245,284,372,382-384,421].
Source [1]: Adapted with permission from Cohen PR, Kurzrock R: Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol 
2003;42:761–778. Copyright 2003, Reprinted with permission from the International Society of Dermatology, Blackwell Publishing Ltd, Oxford, United Kingdom.Orphanet Journal of Rare Diseases 2007, 2:34 http://www.OJRD.com/content/2/1/34
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daily dose of 200 mg of clofazimine for 4 weeks and then
100 mg per day for 4 more weeks. None of the 6 patients
required systemic treatment of their Sweet's syndrome
after the clofazimine was discontinued.
Cyclosporin and dapsone
Cyclosporin and dapsone have been used either as mono-
therapy or in combination with other agents. The initial
oral dose of cyclosporin ranged from 2 mg/kg/day [380]
to 10 mg/kg/day [12,381]; for the patient who was receiv-
ing 10 mg/kg/day, the dose was reduced by 2 mg/kg/day
every 2 days and discontinued on day 21 [12,381]. The
initial oral dose of dapsone ranged from 100 mg per day
to 200 mg per day [17,20,30,203,221,245,284,372,382-
384,421].
Other systemic agents
There are individual case reports of patients with Sweet's
syndrome whose dermatosis has improved after receiving
systemic therapy with antibiotics [7]. For example, these
include individuals whose lesions have become secondar-
ily impetiginized with Staphylococcus aureus; their derma-
tosis-related skin lesions often partially improve after
treatment with an antimicrobial agent to which the bacte-
rial strain is susceptible [23]. The symptoms and lesion of
Sweet's syndrome also resolved in other patients with
inflammatory bowel disease (treated with metronidazole)
[267,387], and persons with dermatosis-related Yersinia
[125,126] or Chlamydia [306,307] infection (treated with
either doxycycline [125,389], minocycline [30,126], or
tetracycline [306,307,388]). Resolution of Sweet's syn-
drome has also been observed following treatment with
other antibiotics such as ciprofloxacin, metronidazole,
penicillin, or pyrimethamine and sulfonamide; some of
these patients also had Sweet's syndrome-associated infec-
tions caused by either group D Salmonella [401], Salmo-
nella typhimurium,  Streptococcus,  Helicobacter pylori, or
Toxoplasma.
Other systemic drugs have also been effective for the treat-
ment of Sweet's syndrome. These observations have pre-
dominantly been described in case reports. The agents
include cytotoxic chemotherapies and antimetabolites
(chlorambucil and cyclophosphamide)
[30,39,148,200,251,360,390], immunoglobulin [303],
interferon alpha [202,366], etretinate [361], and tumor
necrosis factors antagonists (etanercept [392], infliximab
[264,265,278,266], and thalidomide [5,393,425]). Pen-
toxifylline was postulated to be of therapeutic benefit for
treating Sweet's syndrome [394,395]; however, it was not
found to be efficacious when used as monotherapy
[1,2,7,295,362].
Prognosis
Clinical course
In some patients with classical Sweet's syndrome, the
symptoms and lesions of Sweet's syndrome eventually
resolved without any therapeutic intervention. However,
the lesions may persist for weeks to months
[10,23,254,355]. Successful management of the cancer
occasionally results in clearing of the related dermatosis in
patients with malignancy-associated Sweet's syndrome
[13,15,23]. Similarly, spontaneous improvement and
subsequent resolution of the syndrome typically follows
discontinuation of the associated medication in patients
with drug-induced Sweet's syndrome [13,15,23]. In some
of the Sweet's syndrome patients who had dermatosis-
associated tonsillitis, solid tumors, or renal failure, surgi-
cal intervention resulted in the resolution of the dermato-
sis [1,2,19,315,356,357].
Sweet's syndrome may recur following either spontane-
ous remission or therapy-induced clinical resolution [10].
The duration of remission is variable between recurrent
episodes of the dermatosis. In cancer patients, Sweet's syn-
drome recurrences are more common. Indeed, the reap-
pearance of dermatosis-associated symptoms and lesions
in an oncology patient may represent a paraneoplastic
syndrome which is signaling the return of the previously
treated malignancy [1,2,15,135].
Complications
Patients with Sweet's syndrome can develop complica-
tions which are either directly related to the mucocutane-
ous lesions or indirectly related to the Sweet's syndrome-
associated conditions or both. Antimicrobial therapy may
be necessary if the skin lesions may become secondarily
infected. Reappearance of the dermatosis may herald the
unsuspected discovery that the cancer has recurred in
patients with malignancy-associated Sweet's syndrome.
Disease-specific treatment may be warranted for the sys-
temic manifestations of Sweet's syndrome-related condi-
tions such as inflammatory bowel disease, sarcoidosis and
thyroid diseases.
List of abbreviation
kg = kilogram
mg = milligrams
ml = milliliter
SSKI = saturated solution of potassium iodide
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